[Chemoembolization and radioembolization for the treatment of liver metastases]

Pichon Riviere A, Augustovski F, Garcia Marti S, Glujovsky D, Alcaraz A, Lopez A, Bardach A, Ciapponi A
Record ID 32014000273
Authors' objectives: To assess the available evidence on the efficacy, safety and coverage policy related aspects on the use of chemoembolization and radioembolization in patients with liver metastases.
Authors' recommendations: The evidence on the use of chemo and radioembolization for patients with liver metastases is still limited. Although some studies have demonstrated the benefits of these therapies, mainly in studies which added radioembolization to chemotherapy, others did not demonstrate significant differences. There is still no clear evidence if one therapeutic alternative is more beneficial than the other. Its use has been proposed mainly as last line treatment when there are unresectable, refractory metastases only located in the liver. The conclusions obtained from the different HTAs are contradictory and its coverage is mainly accepted, specially for metastases of neuroendocrine origin. More studies are needed to determine if its use may be beneficial in a specific clinical setting.
Project Status: Completed
Year Published: 2012
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: Argentina
MeSH Terms
  • Chemoembolization, Therapeutic
  • Liver Neoplasms
Organisation Name: Institute for Clinical Effectiveness and Health Policy
Contact Address: Dr. Emilio Ravignani 2024, Buenos Aires - Argentina, C1414 CABA
Contact Name: info@iecs.org.ar
Contact Email: info@iecs.org.ar
Copyright: Institute for Clinical Effectiveness and Health Policy (IECS)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.